AZNCF Projected Dividend Yield
Ord/AstraZeneca Plc ( OTCBB : AZNCF )AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in pharmaceutical business focusing on the research, development, manufacturing and commercialization of prescription medicines. Co. is focused on its therapy areas: Oncology, which provides Tagrisso (osimertinib) for lung cancer; BioPharmaceuticals, which provides Farxiga/ Forxiga (dapagliflozin) for Type-2 diabetes, heart failure with reduced ejection fraction and chronic kidney disease; and Rare Disease, which provides Soliris (eculizumab) for paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome, generalised myasthenia gravis and neuromyelitis optica spectrum disorder. 30 YEAR PERFORMANCE RESULTS |
AZNCF Dividend History Detail AZNCF Dividend News AZNCF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
2024 |
N/A |
N/A |
Feb 23, 2024 |
Mar 25, 2024 |
1.9700 |
2024 Total: |
1.9700 |
||||
2023 |
N/A |
N/A |
Aug 11, 2023 |
Sep 11, 2023 |
0.9300 |
2023 |
N/A |
N/A |
Feb 24, 2023 |
Mar 27, 2023 |
1.9700 |
2023 Total: |
2.9000 |
||||
2022 |
N/A |
N/A |
Aug 12, 2022 |
Sep 12, 2022 |
0.9300 |
2022 |
N/A |
N/A |
Feb 25, 2022 |
Mar 28, 2022 |
1.9700 |
2022 Total: |
2.9000 |
||||
2021 |
N/A |
N/A |
Aug 13, 2021 |
Sep 13, 2021 |
0.9000 |
2021 |
N/A |
N/A |
Feb 26, 2021 |
Mar 29, 2021 |
1.9000 |
2021 Total: |
2.8000 |
||||
2020 |
N/A |
N/A |
Aug 14, 2020 |
Sep 14, 2020 |
0.9000 |
2020 |
N/A |
N/A |
Feb 28, 2020 |
Mar 30, 2020 |
1.9000 |
2020 Total: |
2.8000 |
||||
2019 |
N/A |
Aug 08, 2019 |
Aug 09, 2019 |
Sep 09, 2019 |
0.9000 |
2019 |
N/A |
Feb 28, 2019 |
Mar 01, 2019 |
Mar 27, 2019 |
1.9000 |
2019 Total: |
2.8000 |